United Research Laboratories/Mutual Pharmaceutical Co. stated that a court briefing should conclude in October, with oral arguments set for early 2005 for its quinapril HC1 tablets, the generic version of Pfizer's $589 million drug Accupril. It also is actively defending its gabapentin capsules, the generic version of Pfizer's $1.6 billion drug Neurontin.
In other news, the company expects to launch its metaxalone 400 mg tablets, the generic version of King Pharmaceutical's $188 million drug Skelaxin; and its felodipine HCl ER tablets, the generic version of AstraZeneca's $246 million drug Plendil ER, both within the next three months to six months.
COPYRIGHT 2004 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2004 Gale Group
Home
A
8-Hour Bayer
